Pharmaceutical company · UCBJY

UCB
clinical trial
pipeline

Registry checked

Published

Bimekizumab is linked to 7 distinct active studies, with 2 Phase 1, 5 Phase 3. rozanolixizumab is linked to 5 distinct active studies, with 4 Phase 3, 1 Phase 4.

Phase 3 study NCT05077904 in Stereotypical Prolonged Seizures lists estimated primary completion on 29 March 2027. Phase 3 study NCT06055959 in Generalized Myasthenia Gravis lists estimated primary completion on 16 November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

28active trials
as lead sponsor
  • Phase 15
  • Phase 23
  • Phase 318
  • Phase 41
  • Phase not recorded1

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

128 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved later by 53 days

2031-01-23 (estimated)2031-03-17 (estimated)
23 Jan 203117 Mar 2031

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07465289 · ClinicalTrials.gov
Recorded by ComplyRx
27 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000111
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-162210052
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270200244
2026-10-280000000
2026-10-290000000
2026-10-301010021
Type totals34203128 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Bimekizumab

bimzelx

7
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Axial Spondyloarthritis · Enthesitis-related Arthritis · Hidradenitis Suppurativa
Next primary completion
21 December 2026 · estimated
Open drug

rozanolixizumab

rystiggo

5
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 34
  • Phase 41
  • Phase not recorded0
Studied condition
Generalized Myasthenia Gravis · Myasthenia Gravis · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Next primary completion
06 May 2027 · estimated
Open drug

Zilucoplan

zilbrysq

3
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Generalized Myasthenia Gravis · Healthy Participants
Next primary completion
16 November 2026 · estimated
Open drug

Galvokimig

Canonical investigational asset

3
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 23
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Atopic Dermatitis · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis · Non-cystic Fibrosis Bronchiectasis
Next primary completion
17 May 2027 · estimated
Open drug

Brivaracetam

brivaracetamoralsolution · briviact

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Childhood Absence Epilepsy · Epilepsy · Juvenile Absence Epilepsy
Next primary completion
Not reported
Open drug

Dapirolizumab pegol

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Systemic Lupus Erythematosus
Next primary completion
Not reported
Open drug

27 of 28 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 27 of 28 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

UCB trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
ziMyG
Zilucoplan

NCT06055959

Phase 3 · Recruiting

Trial source and qualifications

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: 16 Oct 2024 · actual
    Primary completion: 16 Nov 2026 · estimated
    Study completion: 25 Dec 2026 · estimated

    2021202220232024202520262027202820292030
    A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
    Bimekizumab

    NCT06921850

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-08-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-08-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 07 Apr 2025 · actual
    Primary completion: 21 Dec 2026 · estimated
    Study completion: 06 Mar 2029 · estimated

    2021202220232024202520262027202820292030
    BE UNIQUE
    Bimekizumab

    NCT06506916

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

    5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    5 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 29 Jul 2024 · actual
      Primary completion: 09 Mar 2027 · estimated
      Study completion: 14 Mar 2028 · estimated

      2021202220232024202520262027202820292030
      A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
      Staccato alprazolam

      NCT05077904

      Phase 3 · Recruiting

      Trial source and qualifications

      A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

      7 candidate observations · 3 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 1 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      4 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-08-28 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • pc date moved · Recorded 2026-09-30 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • pc date moved · Recorded 2026-10-27 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 07 Dec 2021 · actual
      Primary completion: 29 Mar 2027 · estimated
      Study completion: 29 Mar 2027 · estimated

      2021202220232024202520262027202820292030
      cosMOG
      rozanolixizumab

      NCT05063162

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 02 Feb 2022 · actual
        Primary completion: 06 May 2027 · estimated
        Study completion: 01 Jul 2027 · estimated

        2021202220232024202520262027202820292030
        PossibILity
        Galvokimig

        NCT07277660

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

        • enrollment change · Recorded 2026-09-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • status flip · Recorded 2026-09-23 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 29 Dec 2025 · actual
        Primary completion: 17 May 2027 · estimated
        Study completion: 06 Mar 2028 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 20 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 1 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        11

        active trials in Neurology

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Neurology11 trials
        • Immunology & Inflammation6 trials
        • Dermatology3 trials
        • Respiratory2 trials
        • Unmapped4 trials
        • Healthy volunteers2 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies
        B

        Biogen

        Shared indexed programme context · 1 selected asset

        Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Canonical current-owner attribution covers 453 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: UCB S.A.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. The additional mixed UCB entity bucket is excluded pending evidence for its individual legal identities.

        ClinicalTrials.gov

        Attribution coverage

        466 distinct registry candidates produced 453 accepted studies. 0 mapped to other owners, 13 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        420 scoped records have indexed enrichment and 33 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-10-31T23:44:13.856Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 2706a2ca068ec72252d1058e7cf174f2aaf7737c3b958becf4a1ad59392d50cf.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 453 mapped lead-sponsored clinical studies across all statuses. 420 have indexed enrichment, 33 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.